SCHEMBL3314554

SCHEMBL3314554

COc1ccc2cc(C3CC(c4ccc(OC)c(OC)c4)=NN3C(=O)c3ccccc3Cl)c(Cl)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
XBP1 P17861 1/20 0.57
KDM4E B2RXH2 3/20 0.51
PKM P14618 2/20 0.51
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPT P10636 4/20 0.50
POLB P06746 2/20 0.50
BLM P54132 1/20 0.50
HTT P42858 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
ABCB1 P08183 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RAB9A P51151 1/20 0.46
HPGD P15428 1/20 0.45
MAOA P21397 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314649 0.94 XBP1 (0.57) XBP1KDM4EPKMKMT2AALDH1A1
SCHEMBL3310619 0.88 KDM4E (0.61) KDM4EPKMKMT2AALDH1A1MAPT
SCHEMBL3311133 0.87 MAOB (0.58) XBP1KDM4EPKMKMT2AMAPT
SCHEMBL3316509 0.86 XBP1 (0.76) XBP1KDM4EPKMKMT2AALDH1A1
SCHEMBL3314397 0.84 ALDH1A1 (0.62) KDM4EPKMKMT2AALDH1A1POLB
SCHEMBL3314426 0.84 KMT2A (0.65) KDM4EKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL3314306 0.84 KMT2A (0.63) XBP1KDM4EPKMKMT2AALDH1A1
SCHEMBL3318263 0.83 KDM4E (0.71) XBP1KDM4EPKMALDH1A1MAPT
SCHEMBL3312789 0.82 KDM4E (0.65) XBP1KDM4EPKMALDH1A1MAPT
SCHEMBL3312868 0.81 KMT2A (0.65) KDM4EPKMKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
WO-2008045663-A2 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS KALYPSYS, INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS PDE4A, PDE4B, PDE4C XBP1 2991/4885KDM4E 332/4885PKM 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.